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Abstract
Introduction Epidemiological evidence strongly links fish oil,
which is rich in docosahexaenoic acid (DHA) and
eicosapentaenoic acid (EPA), with low incidences of several
types of cancer. The inhibitory effects of omega-3
polyunsaturated fatty acids on cancer development and
progression are supported by studies with cultured cells and
animal models. Propofol (2,6-diisopropylphenol) is the most
extensively used general anesthetic–sedative agent employed
today and is nontoxic to humans at high levels (50 µg/ml).
Clinically relevant concentrations of propofol (3 to 8 µg/ml; 20
to 50 µM) have also been reported to have anticancer activities.
The present study describes the synthesis, purification,
characterization and evaluation of two novel anticancer
conjugates, propofol-docosahexaenoate (propofol-DHA) and
propofol-eicosapentaenoate (propofol-EPA).
Methods The conjugates linking an omega-3 fatty acid, either
DHA or EPA, with propofol were synthesized and tested for their
effects on migration, adhesion and apoptosis on MDA-MB-231
breast cancer cells.
Results At low concentrations (25 µM), DHA, EPA or propofol
alone or in combination had minimal effect on cell adhesion to
vitronectin, cell migration against serum and the induction of
apoptosis (only 5 to 15% of the cells became apoptotic). In
contrast, the propofol-DHA or propofol-EPA conjugates
significantly inhibited cell adhesion (15 to 30%) and migration
(about 50%) and induced apoptosis (about 40%) in breast
cancer cells.
Conclusion These results suggest that the novel propofol-DHA
and propofol-EPA conjugates reported here may be useful for
the treatment of breast cancer.
Introduction
Omega-3 polyunsaturated long-chain fatty acids (ω -3 PUFAs)
have been documented to inhibit or even prevent cancer. Epi-
demiological evidence strongly links fish oil (rich in docosahex-
aenoic acid (DHA) and eicosapentaenoic acid (EPA)) with low
incidences of several types of cancer [1-6]. The inhibitory
effects of ω -3 PUFAs on cancer development and progression
are supported by studies using cultured cells and animal mod-
els [7-14]. However, the mechanisms by which ω -3 PUFAs
inhibit cancer remain unclear. Of particular interest are the
many reports demonstrating anticancer properties of ω -3
PUFAs on the growth and survival of various cancer cell lines
cultured in vitro. Included in the growing list of affected cell
lines are breast cancer cells [7,8,15-17]. Several of these
reports indicate that at low concentrations ω -3 PUFAs (10 to
100 µM) produce anticancer effects through the induction of
apoptosis rather than via cytotoxicity. Propofol (2,6 diisopro-
pylphenol) is the most extensively used general anesthetic-
sedative agent employed today [18,19] and is nontoxic to
humans at high levels (3 to 8 µg/ml; 20 to 50 µM) [20]. Pro-
pofol is a potent antioxidant [21-24] and has been shown to
stimulate protein kinase C [25,26], inhibit calcium entry in
muscle cells [27] and increase the calcium sensitivity of myo-
filaments in ventricular myocytes [28]. Propofol is also a potent
direct vasodilator and bronchodilator and has recently been
shown to possess anti-inflammatory and antiseizure
BHT = 2,6-di-tert-butyl-4-methylphenol; Chl = chlorambucil; DEVD-AFC = Asp-Glu-Val-Asp-fluoromethylketone-aminotrifluoromethylcoumarin conju-
gate; DHA = docosahexaenoic acid; DMEM = Dulbecco's modified Eagle's medium; EPA = eicosapentaenoic acid; GC = gas chromatography; ω -
3 PUFAs = omega-3 polyunsaturated fatty acids; TLC = thin-layer chromatography.Breast Cancer Research    Vol 7 No 5    Siddiqui et al.
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properties. Although the exact signaling systems responsible
for these effects are unclear, it does indicate that propofol
alters signaling pathways within cells.
Although most studies concerning the mode of action of pro-
pofol have concentrated on its action as an anesthetic, there
are a few reports indicating that this compound may also affect
cellular processes related to cancer. Clinically relevant con-
centrations of propofol (3 to 8 µg/ml) were reported to
decrease the metastatic potential of human cancer cells,
including HeLa, HT1080, HOS and RPMI-7951 cells [29]. In
addition, continuous infusion of propofol inhibited pulmonary
metastasis of murine osteosarcoma (LM8) cells in mice
through the modulation of Rho A [29]. In HL-60 human promy-
elocytic leukemia cells, propofol was shown to inhibit growth
and induce the formation of apoptotic bodies, increase DNA
fragmentation and laddering, activate caspase-3, caspase-6,
caspase-8 and caspase-9, and induce the cytosolic release of
cytochrome c [30]. The conclusion from these studies was
that propofol induces apoptosis through both a cell-surface
death receptor (extrinsic) and the mitochondrial (intrinsic)
pathway. These studies suggest that propofol possesses anti-
cancer properties in addition to its sedative effects.
The omega-3 PUFAs DHA and EPA are natural nontoxic food
substances that have interesting anticancer properties. Propo-
fol is a widely employed nontoxic anesthetic that also has anti-
cancer properties. Although several preparations of propofol
with lipid mixtures are available for anesthetic usage (Astra-
Zeneca, Wilmington, DE), to our knowledge propofol has not
previously been covalently conjugated with fatty acids. The
purpose of this study was to synthesize and investigate novel
compounds composed of DHA or EPA conjugated to propo-
fol. The conjugates were tested for their ability to inhibit breast
cancer cell migration, alter adhesion to the matrix protein vit-
ronectin and induce apoptosis. The results indicate that these
novel conjugates might represent a new class of anticancer
agents.
Materials and methods
Materials
MDA-MB-231 breast cancer cells were purchased from the
American Type Culture Collection (ATCC; Manassas, VA).
The Vybrant Apoptosis assay kit was from Molecular Probes
(Eugene, OR), and DMEM, penicillin, streptomycin and
glutamine were from Invitrogen Corporation (Grand Island,
NY). Fetal bovine serum was from BioWhittaker (Walkersville,
MD). Transwell chemotaxis chamber plates were from Corning
Incorporated (Corning, NY). Cytomatrix Human Vitronectin-
Coated Strips were from Chemicon International, Inc. (Temec-
ula, CA). DHA and EPA fatty acid standards for thin-layer chro-
matography (TLC) and gas chromatography (GC) were from
Nu-Chek Prep, Inc. (Elysian, MN). Methanol, chloroform, petro-
leum ether, diethyl ether, acetic acid, hexane and ethanol were
from Fisher Scientific (Fair Lane, NY). Propofol, N,N-dicy-
clohexylcarbodiimide, 2,6-di-tert-butyl-4-methylphenol (BHT),
4-(dimethyl amino)pyridine, hematoxylin, crystal violet and all
other reagents were from Sigma Chemical Co. (St Louis, MO).
Synthesis and purification of propofol-DHA and 
propofol-EPA
Although only propofol-DHA synthesis is described here, the
procedure is analogous for the propofol-EPA conjugate. Syn-
thesis was performed in two steps. First, docosahexaenoic
acid anhydride (DHA-anhydride) was synthesized, followed by
its esterification to propofol. Synthesis of the conjugate was
performed under reduced light and under nitrogen to minimize
auto-oxidation. In brief, DHA or EPA (0.300 mmol), a coupling
reagent, N,N-dicyclohexylcarbodiimide (0.45 mmol), and an
antioxidant, BHT (1.5 µM), were dissolved in 5 ml of chloro-
form and the reaction was stirred for 60 min at room tempera-
ture (23–25°C). To this mixture, propofol (0.29 mmol) and 4-
(dimethyl amino)pyridine (0.152 mmol) were added. The mix-
ture was stirred for a period of 12 hours; the suspension was
then filtered, washed with light petroleum (38.3–53.2°C) and
subjected to purification on analytical thin-layer plates (silica
gel, 60 A, 0.2 mm thickness; Alltech Associates, Inc., Deer-
field, IL). The plates were developed in a solvent mixture of
petroleum ether and ethyl acetate (92:8, v/v) and the products
were revealed with iodine vapor. The spots were compared
with authentic DHA, propofol, BHT, pyridine and N,N-dicy-
clohexylcarbodiimide and the spot corresponding to the new
compound was scraped, suspended in chloroform/methanol
(20:80, v/v), passed through a glass filter and stored at -70°C.
The propofol-DHA and propofol-EPA conjugates were charac-
terized as described below.
Characterization of propofol-DHA
Characterization of the propofol-DHA conjugate was per-
formed by a combination of techniques. First, the presence of
propofol in the conjugate was assessed by UV spectroscopy
with an SLM Aminco 3000 spectrophotometer. The conjugate
was dissolved in ethanol and the absorption spectra was
measured from 200 to 600 nm. Next, the new compound was
hydrolyzed and methylated in 3 M methanolic HCl [31]. The
product of the reaction was extracted with hexane/water (2:1,
v/v) and the organic phase was analyzed with a Shimatzu 17A
gas chromatograph with a 0.25 mm × 30 m Stabilwax capillary
column (Resteck, Belfont, PA). The temperature ramp was
180 to 240°C at 3°C/min (hold 3 min), followed by 240 to
245°C at 1°C/min. To determine the presence of a possible
ester group formed in the new product, an infrared spectrum
was taken on a Perkin Elmer/2000FT-IR spectrometer. A thin
film of the product was made by evaporation from chloroform.
Finally, the molecular mass of the product was determined by
mass spectrometry on a MAT95XP mass spectrometer
(Thermo Electron Corp., San Jose, CA) by Dr Jonathan Karty
at the mass spectrometry facility of Indiana University (Bloom-
ington, IN) using an electrospray method.Available online http://breast-cancer-research.com/content/7/5/R645
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Cell culture
MDA-MB-231 breast cancer cells were grown in DMEM con-
taining 10% fetal bovine serum, 100 units/ml penicillin and
100 µg/ml streptomycin at a density of 106 cells/ml for routine
culture. For experimental purposes, cells were cultured at the
cell density indicated and treated with DHA, EPA, propofol or
the conjugates. The test compounds were stored in hexane at
-80°C. An aliquot of the conjugate was dried under nitrogen
and the compounds were diluted in ethanol just before use.
The final concentration of ethanol (less than 0.1%) in the
treated cultures did not exhibit any cytotoxic effects as meas-
ured by lactate dehydrogenase release and a WST-cell prolif-
eration assay (results not shown).
Cell growth assay
The effect of the fatty acids on cell growth was determined
with a WST-1 assay in accordance with the manufacturer's
instructions (Roche Biosciences, Indianapolis, IN).
Cell migration assay
Cell migration was performed with Transwell Chemotaxis
Chamber Plates (Corning Inc.). The bottom chamber was sup-
plemented with 300 µl of DMEM containing 10% fetal calf
serum, and 100 µl of MDA-MB-231 cells (105/ml) in serum-
free DMEM was added to the top chamber with or without
(control) test compounds. The plates were incubated for 4
hours at 37°C in a humidified CO2 incubator. After incubation,
the insides of the inserts were washed and cleaned with cot-
ton swabs, and the filters were fixed with 5% formaldehyde.
The cells were stained with hematoxylin as described [32] and
cells that migrated through the filters were counted under a
microscope on the bottom side of the filters.
Cell adhesion assay
The cell adhesion assay was performed with Cytomatrix
human vitronectin-coated strips (Chemicon International, Inc.,
Temecula, CA). The strips were incubated with 100 µl of
MDA-MB-231 cells (105/ml) at 37°C for 45 min in a CO2 incu-
bator under serum-free conditions with control or test com-
pounds. The wells were washed three times with PBS and the
adhered cells were stained with 0.2% crystal violet in 10%
ethanol for 5 min at room temperature. The excess stain was
removed by washing six times with PBS. The stained cells
were dissolved in 100 µl of solubilization buffer (1:1 mixture of
0.1 M NaH2PO4, pH 4.5, and 50% ethanol) and the absorb-
ance was read at 540 nm. Absorbance of dye in the control
(vehicle-treated) cells was regarded as 100% adherence and
the percentage adherence of treated cells was calculated in
comparison with that of the control cells.
Cell viability and apoptosis assay
A Vybrant apoptosis assay kit (Molecular Probes) was used in
accordance with the manufacturer's protocol. In brief, 100 µl
of MDA-MB-231 cells (105/ml) suspended in serum-free
DMEM were incubated in 96-well plates at 37°C in a humidi-
fied CO2 incubator with control or test compounds. At the end
of the incubation period (24 hours), reagents A (YO-PRO-1,
100 µM) and B (propidium iodide, 1 mg/ml) from the kit were
added to each well (1 µl/ml) and the plates were left to incu-
bate for 30 min on ice. The cells were revealed by using a flu-
orescence microscope with appropriate filters. Live cells do
not exhibit any fluorescence because the dyes are impermea-
ble to living cells, dead and necrotic cells exhibit red fluores-
cence, and apoptotic cells fluoresce green. Total and
apoptotic cells were counted and the percentage of cells
exhibiting apoptosis was calculated.
Caspase-3 activation
Activation of caspase-3 in MDA-MB-231 cells was deter-
mined with a caspase-3 activity assay kit (Oncogenes
Research Products, San Diego, CA). Cells (5 × 105 per well)
were grown in 48-well plates in serum-free DMEM for 24
hours at 37°C in a humidified CO2 incubator with control or
test compounds. After incubation, a caspase-3 fluorescent
substrate (Asp-Glu-Val-Asp-fluoromethylketone-aminotrifluor-
omethylcoumarin conjugate (DEVD-AFC)) was added to each
well (10 µl per well) and the plates were incubated for a further
1 hour. Cells were revealed under a fluorescence microscope
and pictures were taken with a MagnaFire charge-coupled
device camera (Optronics, Goleta, CA).
Cytochrome c release assay
Induction of apoptosis was also assayed by detecting cyto-
chrome c release from the apoptotic cells by western blot anal-
ysis as described [33]. Cells (5 × 105 per well) were grown in
48-well plates in serum-free DMEM for 24 hours at 37°C in a
humidified CO2 incubator with control or test compounds.
Cells were then homogenized in a buffer containing 10 mM
HEPES, pH 7.4, 0.25 mM sucrose and 1 mM EDTA; a post-
nuclear fraction was prepared by centrifugation at 2,000 g for
5 min at 4°C. The supernatant was further centrifuged at
100,000 g for 20 min at 4°C and the resultant cytosolic frac-
tion was used for cytochrome c detection by immunoblotting.
Proteins were separated by 8 to 15% SDS-PAGE and the blot
was incubated with monoclonal anti-cytochrome c (BD Bio-
science Pharmingen, San Diego, CA) or monoclonal antibod-
ies against glyceraldehyde-3-phosphate dehydrogenase
(1:1,000 dilution; Santa Cruz Biotech, Santa Cruz, CA) over-
night at 4°C and detected with secondary anti-mouse peroxi-
dase-conjugated antibodies (Amersham Pharmacia Biotech,
Little Chalfont, Buckinghamshire, UK). The bands were
detected with a chemiluminescence detection kit (Pierce,
Rockford, IL). The relative distributions of cytochrome c and
glyceraldehyde-3-phosphate dehydrogenase (loading control)
were determined by densitometric analysis with the Kodak
imaging system (Eastman Kodak Company, Rochester, NY).
Statistical analysis of data
For each experiment, means and standard errors were found
for each treatment group and were plotted accordingly.Breast Cancer Research    Vol 7 No 5    Siddiqui et al.
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Analysis of variance was performed to test for an overall effect
across treatments. Individual treatments were tested against
the control by using Dunnett's multiple comparison test to con-
trol the Type I experimental wise error. Analyses were con-
ducted with SAS version 8.2 (SAS Institute, Cary, NC).
Results
Characterization of propofol-docosahexaenoate
The chemical synthesis of the propofol-DHA conjugate is
shown in Fig. 1. The initial isolation and characterization of the
synthetic propofol-DHA conjugate were performed with TLC.
The results shown in Fig. 2 demonstrate that reaction between
DHA and propofol resulted in the formation of a new product
with an RF of 0.90. The RF of this product is very different from
that of either DHA or propofol. The band corresponding to the
new compound was scraped and subjected to spectrometric
characterization. The propofol spectra showed two absorption
peaks, at 216 and 274 nm; these peaks were shifted to 205
and 265 nm, respectively, for the propofol-DHA conjugate
(data not shown). Next, the conjugate was hydrolyzed and
then methylated for analysis by gas chromatography. The
results demonstrate that the commercially available propofol
(Aldrich-Sigma Chemical Co.) was 97% pure, and analysis of
the hydrolyzed product of the propofol-DHA conjugate
showed a DHA : propofol ratio of 1: 0.8. The ratio varied from
the expected 1:1 because other isoforms of propofol were
also conjugated to DHA (data not shown).
Further characterization of the conjugate was performed by
infrared spectroscopy. The infrared absorption spectra of the
propofol-DHA conjugate (Fig. 3) showed two broad, strong
absorption bands at 1,750 and 1,250 cm-1, which are attribut-
able to C = O and C–O bonds, respectively, indicating the
presence of an ester. The band at 3,030 cm-1 is characteristic
of an aromatic C–H bond (propofol), and the band at 2,800 to
2,960 cm-1 is characteristic of aliphatic C–H bonds. No O–H
absorption band was seen, indicating the absence of non-
esterified propofol. The presence of an ester bond, aromatic
C–H absorbance, and absence of free O–H group absorb-
ance further confirms the formation of a propofol-DHA
conjugate.
The propofol-EPA conjugate was also synthesized; its charac-
terization by TLC, UV spectroscopy, GC analysis of hydrolyzed
product and infrared spectroscopy was performed in a similar
fashion (data not shown).
Finally, a mass spectroscopic analysis was performed to
determine the molecular mass of the product on a MAT 95XP
high-resolution, high-mass-accuracy mass spectrometer. Its
high mass accuracy (less than 5 p.p.m. in magnetic scan and
Figure 1
Chemical synthesis of the propofol-docosahexaenoic acid (propofol- DHA) conjugate Chemical synthesis of the propofol-docosahexaenoic acid (propofol-
DHA) conjugate. Synthesis was performed in two steps. First, docosa-
hexaenoic acid anhydride (DHA-anhydride) was synthesized with a cou-
pling reagent, N,N-dicyclohexylcarbodiimide (DCC); subsequently, 
conjugation of propofol with DHA was performed in the presence of 4-
(dimethylamino)pyridine (DMAP).
Figure 2
Thin-layer chromatography (TLC) analysis of propofol-docosahexaenoic  acid (propofol-DHA) conjugate synthesis Thin-layer chromatography (TLC) analysis of propofol-docosahexaenoic 
acid (propofol-DHA) conjugate synthesis. Synthesis of propofol-DHA 
was performed as described in the text. The product of the reaction 
was separated by TLC with a light petroleum (38.3–53.2°C)/ethyl ether 
(98:2, v/v) solvent system and the products were revealed with iodine 
vapors. Lane 1, product of the reaction mixture that contained all start-
ing material except propofol; lane 2, product of the complete reaction 
mixture; lane 3, propofol and DHA standards.Available online http://breast-cancer-research.com/content/7/5/R645
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less than 2 p.p.m. in electric scan) enables its data to be used
to provide a formula match. That is, the mass spectra are pre-
cise enough to verify a chemical formula based on the sum of
the mass defects from the constituent atoms. Results demon-
strate that the propofol-DHA mass spectra identified a product
with a parent molecular mass of 488.36 Da, which is very
close to the calculated molecular mass, 488.74 Da. The
observed monoisotopic molecular mass was within 0.8 part
per million (0.0004 atomic mass units) of that predicted for
propofol-DHA. The propofol-EPA spectra identified a product
of molecular mass 462.34 Da, which is very close to the cal-
culated molecular mass of 462.70 Da. The observed monoiso-
topic molecular mass was within 1.1 parts per million (0.0006
atomic mass units) of that predicted for propofol-EPA (see
mass spectrometry data as additional file 1).
Characterization of the propofol-DHA conjugate and propofol-
EPA conjugates suggests that the coupling reaction between
DHA or EPA and propofol resulted in the formation of new
products. The conjugates are a one-to-one ester of DHA or
EPA and propofol.
Effect of DHA, EPA and propofol on cell growth
Results shown in Fig. 4 demonstrate that at 25 µM DHA or
EPA significantly inhibited MDA-MB-231 breast cancer cell
growth by 20 to 30%, whereas only at high concentration
(100 µM) did propofol significantly inhibit breast cancer cell
growth. Subsequent experiments were therefore performed
with a concentration of 25 µM for DHA, EPA, propofol, propo-
fol-DHA and propofol-EPA.
Effect of the conjugates on breast cancer cell migration
Because MDA-MB-231 breast cancer cells are highly inva-
sive, we monitored the effect of the conjugates on cell migra-
tion. The results shown in Fig. 5 demonstrate that DHA, EPA
and propofol alone or in combination do not have a significant
effect on breast cancer cell migration; however, propofol-DHA
and propofol-EPA are equally effective and inhibited cell
migration by about 50% (P < 0.05).
Effect of the conjugates on breast cancer cell adhesion
We also tested the effect of the propofol-DHA and propofol-
EPA conjugates on adhesion of the breast cancer cells to a vit-
ronectin substrate. DHA and EPA alone did not significantly
affect breast cancer cell adhesion, whereas propofol itself or
in combination with DHA or EPA slightly increased cell adhe-
sion (Fig. 6). In contrast, propofol-DHA and propofol-EPA
significantly inhibited cell adhesion by 15% (P < 0.05) and
30% (P < 0.05), respectively.
Effect of the conjugates on breast cancer cell apoptosis
Propofol-DHA and propofol-EPA were tested for their ability to
initiate apoptosis within MDA-MB-231 breast cancer cells.
Induction of apoptosis was assayed by incubating the cells
with DHA, EPA or propofol alone or mixtures of DHA and EPA
with propofol as well as with the propofol-DHA and propofol-
Figure 3
Characterization of propofol-docosahexaenoic acid conjugate by infra- red spectroscopy Characterization of propofol-docosahexaenoic acid conjugate by infra-
red spectroscopy. The infrared spectrum of the conjugate was 
recorded on a Perkin Elmer/2000 FT-IR. The sample was run as a thin 
film after evaporation of solvent. The broad, strong absorption bands at 
1,750 cm-1 and 1,250 cm-1 are attributable to C=O and C–O bonds, 
respectively, and indicate the presence of an ester. The band at 3,030 
cm-1 is characteristic of an aromatic C–H (propofol) and the band at 
2,800 to 2,960 cm-1 is characteristic of aliphatic C–H bonds. No O–H 
absorption band was seen, indicating the absence of nonesterified 
propofol.
Figure 4
Effect of docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA)  and propofol on cellular growth Effect of docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) 
and propofol on cellular growth. Cells (104 per well) were seeded over-
night in a 96-well plate and then treated for 24 hours with various con-
centrations of DHA, EPA or propofol in serum-free medium. Cell growth 
was assayed with a WST-1 assay as described in the Materials and 
methods section. Results are means ± SEM for three experiments. The 
results were analyzed by analysis of variance and Dunnett's multiple 
comparison test to control the Type I experimental wise error. Signifi-
cant differences from the control (P < 0.05) are indicated with an 
asterisk.Breast Cancer Research    Vol 7 No 5    Siddiqui et al.
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EPA conjugates. Results shown in Fig. 7 indicate that, at 25
µM, DHA, EPA or propofol alone induced apoptosis in only 5
to 15% of the cells. Incubating DHA or EPA with propofol did
not further enhance apoptosis, whereas propofol-DHA or
propofol-EPA conjugates were strongly apoptotic, inducing
apoptosis in about 40% (P < 0.05) of the breast cancer cells.
To confirm the apoptotic response in these cells, we further
assayed for caspase-3 activity, a protease involved in the exe-
cution phase of apoptosis. The assay was performed by using
a specific fluorescent caspase-3 substrate (DEVD-AFC) that
on hydrolysis produces a green fluorescent product. The
results shown in Fig. 8 demonstrate that cells incubated with
DHA, EPA or propofol have only a few caspase-3 positive cells
(2 to 5%), whereas many more cells treated with propofol-
DHA or propofol-EPA conjugates exhibited caspase-3 activa-
tion (15 to 20%).
The effect of propofol-DHA and propofol-EPA conjugates on
apoptosis was further analyzed by assaying for cytochrome c
release (Fig. 9). DHA, EPA and propofol alone had no signifi-
cant effect on cytochrome c release, whereas DHA or EPA
with propofol caused an approximately 150 to 200% (P <
0.05) increase in cytochrome c release. However, propofol-
DHA or propofol-EPA conjugates caused significant increases
in cytochrome c release by about 300 to 400% (P < 0.05).
These results confirm that the propofol-DHA and propofol-
EPA conjugates are far more effective at inducing apoptosis in
breast cancer cells than are the unconjugated parent com-
pounds DHA, EPA or propofol.
Discussion
Often a major obstacle to the successful use of a drug is its
ability to be taken up and retained by cells. Either the drug
must have its target on the outer membrane surface or it must
cross the plasma membrane through either an existing trans-
port system or by simple diffusion to affect intracellular targets.
One approach to overcoming the problem of cell entry and
retention has been to link water-soluble drugs to lipophilic
carriers. Several attempts have been made in the past to syn-
thesize novel compounds by conjugating fatty acids with
drugs. For example, chlorambucil-fatty acid conjugates (Chl-
fatty acid) were synthesized and tested on human lymphoma
cell lines [34]. These studies found that the conjugates
(including those with DHA) selectively affected neoplastic lym-
phocytes, with minimal effect on quiescent lymphocytes [34].
The cell toxicity observed with Chl-arachidonic acid and Chl-
docosahexaenoic acid against lymphoma cells was equal to or
higher than the individual toxic potential of either chlorambucil
Figure 5
Effect of propofol-docosahexaenoic acid (propofol-DHA) and propofol- eicosapentaenoic acid (propofol-EPA) conjugates on cell migration Effect of propofol-docosahexaenoic acid (propofol-DHA) and propofol-
eicosapentaenoic acid (propofol-EPA) conjugates on cell migration. 
MDA-MB-231 cells (104) were incubated for 4 hours with 25 µM DHA 
(D), 25 µM EPA (E), 25 µM propofol (P), 25 µM each of D+P, 25 µM 
each of E+P, and 25 µM propofol-DHA (D-P) or 25 µM propofol-EPA 
(E-P) using transwell plates. The control cells (C) were treated with 
equal amounts of ethanol. Cells that migrated through the filter were 
counted under a microscope as described in the text. Results are 
means ± SEM for four experiments. The results were analyzed by analy-
sis of variance and Dunnett's multiple comparison test to control the 
Type I experimental wise error. Significant differences from the control 
(P < 0.05) are indicated with an asterisk.
Figure 6
Effect of propofol-docosahexaenoic acid (propofol-DHA) and propofol- eicosapentaenoic acid (propofol-EPA) conjugates on cell adhesion Effect of propofol-docosahexaenoic acid (propofol-DHA) and propofol-
eicosapentaenoic acid (propofol-EPA) conjugates on cell adhesion. 
MDA-MB-231 cells (104) were incubated in vitronectin-coated plates in 
the presence of 25 µM DHA (D), 25 µM EPA (E), 25 µM propofol (P), 
25 µM each of D+P, 25 µM each of E+P, and 25 µM propofol-DHA (D-
P) or 25 µM propofol-EPA (E-P) for 45 min. The control cells were 
treated with equal amounts of ethanol. Cells adhering to the plates 
were quantified by staining and measurement of the absorbance in a 
spectrophotometer as described in the text. Results are means ± SEM 
for four experiments and are presented as the percentages of adhered 
cells in comparison with the controls. The results were analyzed by 
analysis of variance and Dunnett's multiple comparison test to control 
the Type I experimental wise error. Significant differences from the con-
trol (P < 0.05) are indicated with an asterisk.Available online http://breast-cancer-research.com/content/7/5/R645
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or the fatty acids, whereas the Chl-oleic acid conjugate was
much less toxic than Chl alone. The authors concluded that
the coupling of chlorambucil with polyunsaturated fatty acids
was selective against neoplastic versus quiescent lym-
phocytes [34]. During the present investigation, propofol was
conjugated with the omega-3 fatty acids DHA and EPA. It is
possible that propofol conjugated with arachidonic acid, an
omega-6 polyunsaturated fatty acid, or with a saturated fatty
acid might be as effective. However, there is now a large body
of evidence that DHA and EPA are far more effective than
shorter and less unsaturated fatty acids [35]. Clearly addi-
tional studies are needed to establish the specificity of propo-
fol conjugates with different fatty acids.
Similarly, DHA-paclitaxel was synthesized by Bradley and col-
leagues, who demonstrated that the conjugate possessed
antitumor activity in mice with lung tumors [36]. In the M109
mouse tumor model, DHA-paclitaxel was less toxic to animals
than paclitaxel alone and cured all tumor-bearing animals; in
contrast, unconjugated paclitaxel cured none. This study indi-
cated a limited plasma area under the drug concentration–
time curve (AUC) for paclitaxel, and an increase in tumor AUC
of DHA-paclitaxel administration was consistent with the
increase in therapeutic index of DHA-paclitaxel relative to pacl-
itaxel in the M109 mouse tumor model. During the present
investigation we did not measure the tissue concentrations of
propofol, DHA or EPA after treatment with propofol-DHA or
propofol-EPA, but we plan to do so in a further study.
We have previously employed the DHA-conjugate approach
to enhance the availability and hence the activity of the anti-
cancer drug methotrexate [37]. Two phosphatidylcholines
were synthesized to contain methotrexate in the sn-2 position
and either stearic acid or DHA in the sn-1 position. The DHA-
containing and methotrexate-containing phosphatidylcholines
were more effective than conjugates containing stearic acid.
Synthesis of phosphatidylcholines containing DHA and propo-
fol is also a possibility, but such a synthesis is more cumber-
some. In the study described here, we therefore used another
approach to synthesize a class of novel compounds by directly
conjugating DHA or EPA with propofol. Results presented in
Figs 1 to 4 show that our synthetic process produced the pro-
pofol-DHA and propofol-EPA conjugates. Separations by TLC
(Fig. 2), UV absorption, hydrolysis and GC analysis (not
Figure 7
Effect of propofol-docosahexaenoic acid (propofol-DHA) and propofol- eicosapentaenoic acid (propofol-EPA) conjugates on breast cancer cell  apoptosis Effect of propofol-docosahexaenoic acid (propofol-DHA) and propofol-
eicosapentaenoic acid (propofol-EPA) conjugates on breast cancer cell 
apoptosis. MDA-MB-231 cells (104) were incubated with 25 µM DHA 
(D), 25 µM EPA (E), 25 µM propofol (P), 25 µM each of D+P, 25 µM 
each of E+P, 25 µM propofol-DHA (D-P) or 25 µM propofol-EPA (E-P) 
for 24 hours. The control cells (C) were treated with equal amounts of 
ethanol. The apoptotic cells were stained by using the Vybrant Apopto-
sis assay kit as described in the text. Results are means ± SEM for four 
experiments. The results were analyzed by analysis of variance and 
Dunnett's multiple comparison test to control the Type I experimental 
wise error. Significant differences from the control (P < 0.05) are indi-
cated with an asterisk.
Figure 8
Effect of propofol-docosahexaenoic acid (propofol-DHA) and propofol- eicosapentaenoic acid (propofol-EPA) conjugates on caspase-3  activation Effect of propofol-docosahexaenoic acid (propofol-DHA) and propofol-
eicosapentaenoic acid (propofol-EPA) conjugates on caspase-3 activa-
tion. MDA-MB-231 cells (5 × 105 per well) were grown in 96-well 
plates for 24 hours at 37°C in a humidified CO2 incubator with control 
or test compounds. Cells containing activated caspase-3 fluoresced 
green as the result of cleavage of a fluorogenic substrate (Asp-Glu-Val-
Asp-fluoromethylketone-aminotrifluoromethylcoumarin conjugate).Breast Cancer Research    Vol 7 No 5    Siddiqui et al.
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shown), infrared spectroscopy (Fig. 3) and mass spectros-
copy (not shown) confirm the identity of the conjugates.
After obtaining the conjugates, we investigated their antican-
cer effects on breast cancer cells. MDA-MB-231 is a highly
invasive breast cancer cell line that has the potential for uncon-
trolled proliferation and metastasis in animal models [38]. We
investigated the effects of these novel conjugates on cell
migration, adhesion and cancer cell death through apoptosis.
Results presented in Fig. 5 show that the conjugates do
indeed inhibit cell migration, whereas DHA, EPA or propofol at
the same concentration has no effect. We then assayed these
compounds for their effect on cell adhesion to a vitronectin
substrate. Results in Fig. 6 show that DHA or EPA alone or in
combination with propofol did not inhibit cancer cell adhesion,
whereas the same concentrations of propofol-DHA and pro-
pofol-EPA caused significant inhibition. Cell migration and
adhesion are essential processes in tumor metastasis [39].
The results of this study suggest that these novel conjugates
are able to affect the metastatic potential of this breast cancer
cell line by inhibiting both migration and adhesion at concen-
trations at which DHA, EPA or propofol alone are not effective.
We then further analyzed the effect on these conjugates on
the induction of apoptosis. Results in Fig. 7 show that both
conjugates are able to induce apoptosis (Vybrant apoptosis
assay kit) in breast cancer cells. Induction of apoptosis was
further confirmed by assaying for caspase-3 activation (Fig. 8)
and cytochrome c release (Fig. 9). Cytochrome c has a func-
tion in the intrinsic pathway of apoptosis and leads to the acti-
vation of caspase-3, which is a downstream enzyme in the
apoptosis process and is involved in the execution phase of
the death pathway [40]. Release of cytochrome c and activa-
tion of caspase-3 by propofol-DHA and propofol-EPA conju-
gates confirm that these compounds induce a cell signaling
pathway for apoptosis that eventually leads to the death of
breast cancer cells.
During the present study, the detailed molecular mechanisms
by which these conjugates inhibit migration and adhesion and
induce apoptosis were not investigated. Our previous studies
[41-43] and other reports [44,45] have shown that DHA is
rapidly taken up by cells and incorporated into membrane
phospholipids. Propofol, being a partly lipophilic agent, also
interacts with cellular membranes [46]. However, because of
its volatile nature, it is rapidly removed from membranes and
has a very short half-life in the circulation [19]. It is possible
that these conjugates provide a mechanism whereby propofol
can be retained in cell membranes for a longer duration and
therefore enhance its anticancer effects. Studies have shown
that the incorporation of DHA into membranes results in reor-
ganization and the formation of membrane microdomains [47].
These conjugates might therefore influence cell-signaling
pathways involved in cell migration, adhesion and apoptosis.
We have previously shown that DHA induces apoptosis in Jur-
kat leukemic cells by activating protein phosphatases [48,49].
We have not yet tested this possibility with the conjugates;
however, it is likely that these conjugates also activate protein
phosphatases, inducing apoptosis. Further investigation is
required to explore the molecular mechanisms by which pro-
pofol-DHA and propofol-EPA conjugates affect the growth,
migration and adhesion of breast cancer cells. We also plan to
investigate the effect of the conjugates on other cancer cell
lines. Importantly, our preliminary observations indicate that
similar concentrations of these conjugates do not induce any
cytotoxic effects in normal skeletal muscle cells, cardiomyo-
cytes or hepatocyte cell lines from rat (data not shown). Fur-
ther studies are required to test these compounds on normal
human cell lines.
Figure 9
Effect of propofol-docosahexaenoic acid (DHA) and propofol-eicosap- entaenoic (EPA) conjugates on cytochrome c release Effect of propofol-docosahexaenoic acid (propofol-DHA) and propofol-
eicosapentaenoic (propofol-EPA) conjugates on cytochrome c release. 
MDA-MB-231 cells (0.5 × 106/well) were grown in 96-well plates for 
24 hours at 37°C in a humidified CO2 incubator with control or test 
compounds. (a) Postnuclear supernatant was used for the determina-
tion of cytochrome c release using immunobloting as described in the 
Materials and Methods section. The relative distributions of cytochrome 
c and glyceraldehyde-3-phosphate dehydrogenase (loading control) 
were determined. (b) Quantification was by densitometry analysis with 
the Kodak imaging system. Results are means ± SEM for three experi-
ments. The results were analyzed by analysis of variance and Dunnett's 
multiple comparison test to control the Type I experimental wise error. 
Significant differences from the control (P < 0.05) are indicated with an 
asterisk. D, 25 µM DHA; E, 25 µM EPA; P, 25 µM propofol; D+P, 25 
µM DHA plus 25 µM propofol; E+P, 25 µM EPA plus 25 µM propofol; 
D-P, 25 µM propofol-DHA; E-P, 25 µM propofol-EPA.Available online http://breast-cancer-research.com/content/7/5/R645
R653
Conclusion
Our synthesis has yielded two novel lipid compounds, namely
propofol-DHA and propofol-EPA. These conjugates exhibit
anticancer effects that include the inhibition of cell migration
and adhesion and the induction of apoptosis within MDA-MB-
231 breast cancer cells. The conjugates are more active than
the parent compounds and possess unique anticancer activi-
ties not found with the latter (namely inhibition of adherence).
These conjugates were not tested in other breast cancer cell
lines or other cancers of different anatomical locations. Exper-
iments are under way to test these conjugates on different
cancer cells lines and also in model systems in vivo.
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